- Conditions
- Obesity (Disorder), Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 678
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Biospecimen Collection, Goserelin Acetate, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, letrozole
- Biological · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer
- Interventions
- Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
- Drug
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Gresham, Oregon • Portland, Oregon • Tualatin, Oregon + 1 more
- Conditions
- Breast Cancer
- Interventions
- NeuVax vaccine, Trastuzumab, GM-CSF
- Biological · Drug
- Lead sponsor
- Cancer Insight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 24
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Breast Cancer
- Interventions
- Anastrozole, Risedronate Sodium
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Pembrolizumab, Palliative radiotherapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 60 Years to 75 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- Palbociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Stereotactic Radiation Therapy, Endocrine Therapy
- Radiation · Drug
- Lead sponsor
- Renaissance Institute of Precision Oncology and Radiosurgery
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Winter Park, Florida
- Conditions
- Breast Cancer, Primary Hormone Receptor Positive Breast Cancer
- Interventions
- Exercise Treatment, Plant-Based Diet, Physical activity, Nutrition counseling, Replication Exercise Test
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
- Interventions
- LDE225, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
- Interventions
- Alpelisib, Tamoxifen, Zotatifin, Fulvestrant
- Drug
- Lead sponsor
- Jennifer Lee Caswell-Jin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Breast Neoplasms
- Interventions
- exemestane, sunitinib malate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
- Interventions
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
- Conditions
- Advanced Breast Cancer
- Interventions
- Ribociclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
- Interventions
- Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 4
- States / cities
- Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Interventions
- AZD8931, anastrozole, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
- Interventions
- Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 32
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Interventions
- ONC201
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Vandetanib, Anastrozole
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California